Trials / Completed
CompletedNCT01019577
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
Phase II Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- R-Pharm · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2009-11-25
- Last updated
- 2017-01-30
Source: ClinicalTrials.gov record NCT01019577. Inclusion in this directory is not an endorsement.